Crenolanib

Crenolanib

CAT N°: 18873
Price:

From 71.00 60.35

Crenolanib is an orally bioavailable, selective inhibitor of type III tyrosine kinases with nanomolar potencies against platelet-derived growth factor receptor ? (PDGFR?) and PDGFR? and Fms-related tyrosine kinase 3 (FLT3; IC50s = 11, 3.2, and 4 nM, respectively).{30695,30696} It also inhibits medically-relevant mutant forms of these kinases, including the D842V-containing form of PDGFR and D835Y and internal tandem duplication mutations of FLT3, at nanomolar concentrations.{30695,30693,30694} Crenolanib is more than 100-fold selective for these kinases over other tyrosine and serine/threonine kinases. It is effective when used in cells and in vivo.{30695,30696,30694}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 1-?[2-?[5-?[(3-?methyl-?3-?oxetanyl)?methoxy]?-?1H-?benzimidazol-?1-?yl]?-?8-?quinolinyl]?-4-?piperidinamine
  • Correlated keywords
    • 866109-23-1 CP868596 ARO 002 ARO002 PDGFR?/? FLT3 PDGFR? PDGFR? FLT-3 PDGFR ? ? type III platelet-derived growth factor receptor PDGFRa/b PDGFRa PDGFRb Fms-related tyrosine kinase CP868,596 CP-868596 CP-868,596
  • Product Overview:
    Crenolanib is an orally bioavailable, selective inhibitor of type III tyrosine kinases with nanomolar potencies against platelet-derived growth factor receptor ? (PDGFR?) and PDGFR? and Fms-related tyrosine kinase 3 (FLT3; IC50s = 11, 3.2, and 4 nM, respectively).{30695,30696} It also inhibits medically-relevant mutant forms of these kinases, including the D842V-containing form of PDGFR and D835Y and internal tandem duplication mutations of FLT3, at nanomolar concentrations.{30695,30693,30694} Crenolanib is more than 100-fold selective for these kinases over other tyrosine and serine/threonine kinases. It is effective when used in cells and in vivo.{30695,30696,30694}

We also advise you